

UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
BOARD OF DIRECTORS
THURSDAY 26 SEPTEMBER 2013

Title:	BOARD ASSURANCE FRAMEWORK
Responsible Director:	David Burbridge, Director of Corporate Affairs
Contact:	Bob Hibberd, Head of Clinical Risk and Compliance

Purpose:	To provide the BoD with the high level risks within the context of the Board Assurance Framework
Confidentiality Level & Reason:	None
Medium Term Plan Ref:	Annual Plan
Key Issues Summary:	<ul style="list-style-type: none">• There are 0 high severity residual risks and 5 significant risks.• All other risks are moderate or low.
Recommendations:	The BoD is asked to: <ul style="list-style-type: none">• Discuss the contents of this report• Approve the Board Assurance Framework

Approved by: DAVID BURBRIDGE	Date: 18 September 2013
-------------------------------------	--------------------------------

UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
BOARD OF DIRECTORS
THURSDAY 26 SEPTEMBER 2013
BOARD ASSURANCE FRAMEWORK

Presented by Director of Corporate Affairs

1 REVIEW

- 1.1 The Board (July 2013) has approved the key risks to the Trust's objectives which have been included in the Board Assurance Framework (BAF).
- 1.2 The Board Assurance Framework (BAF) has been reviewed and updated with the relevant Executive Directors.
- 1.3 The Trust has identified a range of strategic significant risks, which are currently being mitigated, whose impact could have a direct bearing on compliance with the Terms of Authorisation, CQC registration or the achievement of corporate objectives in the following areas should the mitigation plans be ineffective.
- 1.4 Currently, the significant risks relate to the following areas:
- 1.4.1 **Finance - The Trust fails to achieve a satisfactory financial risk rating** Core purpose 1
 - 1.4.2 **Strategic- Strategies are not able to respond to external changes and system pressures** Core purpose 1
 - 1.4.3 **Compliance - Breach of terms of Monitor Provider Licence/Material non-compliance with external regulatory requirement** Core purpose 1
 - 1.4.4 **Strategic Inability to adapt to meet changing needs of patient population** Core Purpose 1
 - 1.4.5 **Operational - Failure in one or more components of business and IT systems, resulting in clinical service, department, equipment and/or staffing failure** Core purpose 1

2 RECOMMENDATIONS

- 2.1 The BoD is asked to:
- 2.1.1 Discuss the contents of this report
 - 2.1.2 Approve the Board Assurance Framework

Board Assurance Framework Report

Annual Plan		CORE PURPOSE 1: CLINICAL QUALITY - Strategic Aim: To deliver and be recognised for the highest levels of quality evidenced by technology, information, and benchmarking								
Corporate Objective		Strategic Enabler 1 : To strengthen the organisational systems and arrangements for the collection, access, use, and reporting of quality outcomes to key stakeholders								
Ref	Description	Risk Context			Initial Risk		Current Effectiveness	Owner	Review Date	Residual Risk
Financial	05. STRATEGIC Significant deterioration of Trust's underlying financial position				Moderate	Low (Within Tolerance)	Mike Sexton		29/11/2013	Low (Within Tolerance)
Controls		Gaps			Assurances		Effectiveness		External	
Description	CFS: Appropriate and accurate levels of Delegation and Authorisation, limits.	Risk of fraud will never be completely mitigated.			Internal		Regular report to the Audit Committee. Audit committee minutes. Annual plan of work agreed by Audit Committee and reports provided to Audit Committee as work is completed. Scheme of Delegation. Internal policies and procedures. SAGE system. Scheme of delegation published within Trust Policies and reviewed regularly.		Counter Fraud Service Assessment. SFIs/Standing Orders. External assessment of effectiveness of Counter Fraud Service assessed as Adequate in 2012. Scheme of financial systems (SAGE) reflects the approved SFIs and Scheme of Delegation therefore setting appropriate limits for procurement.	
Ref	Description	Risk Details			Initial Risk		Current Effectiveness	Owner	Review Date	Residual Risk
Financial	06. STRATEGIC The Trust fails to achieve a satisfactory financial risk rating				Significant	Significant	Mike Sexton		29/11/2013	Significant
Controls		Gaps			Assurances		Effectiveness		External	
Description	Annual Financial Plan, Monitor 3 Year Financial Plan, Monthly Finance and Activity Performance Report. Quarterly reports to Monitor.	The Trust has achieved a Financial Risk Rating of 3 for 2012/13. It is expected that this will be maintained in 2013/14.			Internal		Downside plan, 3 year financial plans updated annually. Internally the Trust maintains a 10 year financial plan which is reviewed at Audit Committee and Bod Audit Committee Minutes.		External / Audit of Annual Accounts, External Review of 3 Year Plans. The Trust provides quarterly returns to Monitor outlining the Trusts current financial performance against the plan. Internal audit validation of systems.	
Corporate Objective		Strategic Enabler 2: To deliver and communicate the best in quality outcomes			Risk Details		Initial Risk		Review Date	
Ref	Description				CQC Outcome 16	High	Moderate	Kay Fawcett	29/11/2013	Moderate
Controls		Gaps			Assurances		Effectiveness		External	
Description	Back To The Floor (BTTF). Regular review of patient environment, documentation and standards of care is undertaken by a Marion with ward staff. A series of audit tools have been designed which can be used for themed reviews such as care rounds.				Internal		Electronic BTTF system, Clinical Dashboard, Senior Nurse forum meeting minutes. BTTF action plans on Clinical Dashboard. Divisional BTTF meetings. Nursing Grand Round minutes.		Audit process for assurance of compliance.	
Controls		Gaps			Assurances		Effectiveness		External	
Description	CQC inspection reports and action plans				M	M	CQC action plans developed by local areas. Monitored at Mental Health Group/Care Quality Group/Clinical Quality Monitoring Group.		CQC visit reports. Internal audit reports/Audit committee reports/minutes	
Controls		Gaps			Assurances		Internal		External	
Description	Infection Prevention and Control Action Plan. Monthly review of risks, controls and compliance for IP&C. RCA review of all cases MRSA and CDI. Local review of CDI, RCA and Executive Review of Trust Appointed cases of MRSA bacteraemia and CDI deaths. Robust process for review of policy and procedures.				Effectiveness		Minutes from IP&C Bod, CFA/G, IP&CC Divisional IP & C Task matrices, Data reports, RCA themes and trends, IP&C action plans. IP&C Dashboard, Training records.		DH reporting guidance and notifications of outbreaks. Joint working with CCG to achieve primary and secondary care continuity of treatment. CQC visit report. Department of health MRSA Post Infection Review (PIR) approach to zero avoidable MRSA bacteraemias.	
Controls		Gaps			Assurances		Internal		External	
Description	Learning from Complaints/PALS Incidents/Claims				M	M	Complaint/PALS responses. SIRI reports and action plans. Risk Management Reports. Risk registers. CEAG Papers. Care Quality Group reports. CQMG reports. DCQMG framework dashboard. Reports to Bod		CQC inspections/reports. NHS LA RMS assessments. Development of more robust system for follow up of trends and actions.	
Controls		Gaps			Effectiveness		Internal		External	
Description					M	M	Assurances		Gaps	

M Care Quality Group reports/minutes, CEA/G/BoD reports. Audit of noise at night action plans.
National Patient Survey results. BTTF initiative findings.

Risk Register							
Ref	Description	Risk Details	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Strategic	04 - STRATEGIC UHB Strategies are not able to respond to external changes and system pressures	Risk Context CCG Commissioning intentions	Significant	Significant	Tim Jones	29/11/2013	Significant
Controls		Gaps Assurances	Effectiveness Internal	Minutes from CIG. Development of partnerships with consortia and lead commissioners. Develop further relationships with consortia lead GPs. Emerging issues to be developed with embedding of Associate Director of Partnerships post. Future meetings to be centered on service level and contractual arrangements.	Working relationships with CCG, SHA and shadow consortia leads. CIG TOR.		Gaps A process for developing 2013-14 commissioning intentions to reflect clinicians priorities to be established.
Controls		Gaps Assurances	Effectiveness Internal	Quarterly Monitor reports to BoD. Feedback from Executive meetings with Government leads to establish influence over policy and strategy.	Quarterly reports to Monitor. Develop more links with influential departments and key staff.		Gaps Stakeholder Strategy in development for submission to the BoD.
Controls	Description CEO, links with Monitor/CQC. Strategies approved by BoD.	Gaps Assurances	Effectiveness Internal	Regular meetings with commissioners and significant external partners. Governance arrangements that feed into Trust structures.	Clinical Commissioning Contract Board established with monthly meeting schedule. Membership of partnership groups revised to incorporate Trust governance arrangements. Membership established of cluster wide system plan group. Meetings with PCT.		Gaps Clinical Commissioning Contract Board established with monthly meeting schedule. Membership of partnership groups revised to incorporate Trust governance arrangements. Membership established of cluster wide system plan group. Meetings with PCT.
Controls	Description Clinical Interface/Contract meetings. Involvement in external partnerships. Clinical Commissioning Contract Board established with monthly meeting schedule.	Gaps Assurances	Effectiveness Internal	BoD reports and minutes. Dashboards, Board seminars, business planning capability.	Monitor validation of Trust financial and governance arrangements.		Gaps Horizon scanning to identify consistency for Trust planning 2013-14.
Controls	Description Health and Social Care Bill Commissioning support unit. Changes to Monitor. National Commission Board.	Gaps Assurances	Effectiveness Internal	H			
Ref	Description	Risk Details	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Compliance	10 - STRATEGIC Risk of prosecution of Trust and/or individual directors or members of staff	Risk Context Francis Report recommendations	High	Moderate	David Burbidge	29/11/2013	Moderate
Controls		Gaps Assurances	Effectiveness Internal	Incident reporting. Reports to Audit Committee and BoD. Health and Safety Policy. Governance Framework. Monitoring Report to BoD.			
Ref	Description	Risk Details	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Compliance	11 - STRATEGIC Breach of terms of Monitor Provider Licence/Material non-compliance with external regulatory requirement	Risk Context Governance Framework to be completed by April 2013. Dashboards and reports still in development. Health Assure system issues identified and working with Allocate to resolve.	Significant	Significant	David Burbidge	29/11/2013	Significant
Controls		Gaps Assurances	Effectiveness Internal	Board Meeting Minutes. Quarterly paper.			
Corporate Objective	Strategic Enabler 3: To improve quality and efficiency along the patient pathway working with local health economy partners	Risk Details	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Strategic	02 - STRATEGIC inability to adapt to meet changing needs of patient population		Significant	Significant	Andrew McKigan	29/11/2013	Significant
Controls	Description	Gaps Assurances	Effectiveness Internal				Gaps

Corporate Objective		Strategic Enabler 4: To ensure care is delivered using the best available treatment and technology that produces the best clinical outcomes					
Controls		Risk Details					
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Operational	03. STRATEGIC Lack of clarity and/or leadership in the national and local health and social care landscape	Moderate	Moderate	Tim Jones	29/11/2013	Moderate	Gaps
Controls	Description	Gaps	Effectiveness Internal	Assurances	External	Review Date	Residual Risk
Corporate Objective		Strategic Enabler 4: To ensure care is delivered using the best available treatment and technology that produces the best clinical outcomes					
Controls		Risk Details					
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Operational	08. STRATEGIC Failure in one or more components of business and IT systems, resulting in clinical service, department, equipment and/or staffing failure	Significant	Significant	David Rosser/Kevin Belger	29/11/2013	Significant	Gaps
Controls	Description	Gaps	Effectiveness Internal	Assurances	External	Review Date	Residual Risk
Annual Plan		Strategic Enabler 4: To ensure care is delivered using the best available treatment and technology that produces the best clinical outcomes					
Corporate Objective		Risk Details					
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Reputational	13. STRATEGIC Adverse media coverage related to Trust activities with a risk of reputational damage	H	Moderate	Fiona Alexander	29/11/2013	Moderate	Gaps
Controls	Description	Gaps	Effectiveness Internal	Assurances	External	Review Date	Residual Risk
Corporate Objective		Strategic Enabler 3: To develop the Trust culture and staff behaviour to focus on the patient experience and ensure improved engagement with marginalised groups					
Controls		Risk Details					
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Reputational	12. STRATEGIC Patient experience fails to match expectations	Moderate	Low (Within Tolerance)	Kay Fawcett	29/11/2013	Low (Within Tolerance)	Gaps
Controls	Description	Gaps	Effectiveness Internal	Assurances	External	Review Date	Residual Risk

Care Quality Group, reports from informatics on key indicators. Patient Services and PALS integrated into Patient Relation Service from July 2012. To ensure effective complaint management and review action for common themes.

Trustwide learning from complaints and PALS feedback to be embedded. Regular reports to BoD/Audit Committee. Gaps in assurance - Operational outputs from strategy. Care Quality Group receive a quarterly report detailing themes from all aspects of patient feedback.

Corporate Objective		Strategic Enabler 4: To strengthen cross-organisation partnerships with the new Clinical Commissioning Groups and other organisations within and outside the NHS				Residual Risk	
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Gaps
Reputational	14. STRATEGIC Reputational/financial/organisational damage arising from commercial ventures	Moderate	Moderate	Kevin Bolger		29/11/2013	Moderate
Controls	Description	Gaps	Effectiveness	Internal	Assurances	External	Gaps
Description	Executive Director Strategic Operations (and External Affairs) and Business Manager - International Partnerships roles have been developed and recruited to.	Strategies to be developed to support Trust, identification of opportunities and clarification of areas to pursue continues.	Private Patient Strategy. Board Seminar in July 2013 to discuss developments re internal relationships.	H			Follow-up at further Board meetings to be identified.
Annual Plan	CORE PURPOSE 3: EDUCATION AND TRAINING - Strategic Aim: To create a fit for purpose workforce for today and tomorrow						
Corporate Objective	Strategic Enabler 1: To strengthen the Trust's capacity and capability for developing and managing the workforce				Risk Details		
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Organisational	07. STRATEGIC Insufficient resources, particularly in terms of senior management availability, to effectively plan and prepare for a major organisational change with detrimental impact on the Trust's core business	Significant	Low (Within Tolerance)	Andrew McKigan		29/11/2013	Low (Within Tolerance)
Controls	Description	Gaps	Effectiveness	Internal	Assurances	External	Gaps
Description	Junior doctor dashboard has been developed. Part of this system is to identify errors earlier.	Further dashboard development.			Dashboard, Grand Round teaching sessions for FY1 and FY2.		
Controls	Description	Gaps	Effectiveness	Internal	Assurances	External	Gaps
Description	Retention of key staff; Clear and prioritised departmental objectives; and appraisal system. Internal control systems which minimise demands on senior staff time.	Middle management recruitment to be implemented in all Divisions.	Appraisal rates, senior management turnover rates; Regular senior team meetings, including periodic review of departmental objectives and of senior managers' individual objectives; internal audit review to confirm the reliability of financial records and compliance with Trust policies and regulations.	H		External audit reports and action plans review to confirm the reliability of financial records and compliance with Trust policies and regulations.	
Controls	Description	Gaps	Effectiveness	Internal	Assurances	External	Gaps
Description	SDG. Establish the Trusts Education and Training directorate and implement appropriate procedures. A Physicians Steering Group has also been established. In response to the White Paper: Liberating the NHS, the education has been reviewed and an action plan developed to provide training to medical and nursing staff.	Remodelling of Trust workforce to commence in Q4 2012-13.	Reports to BoD, KPI evidence reports. Staff survey, Successful award and project outcomes. Approved Training and Education Strategy. Training records and ESR. Education Directorate Senior Team meetings with Divisions. Education Directorate Business plans. Physicians Steering Group minutes.			NHS White Paper Liberating the NHS. NMC Review of UHBTT Mentorship Programme (in conjunction with University Education Providers) carried out in March 2011 with a favourable report.	
Annual Plan	CORE PURPOSE 4: RESEARCH AND INNOVATION- Strategic Aim: To ensure UHB is a leader of research and innovation						
Corporate Objective	Strategic Enabler 1: To strengthen and consolidate the Trust's capacity and capability to enable research and development				Risk Details		
Ref	Description	Risk Context	Initial Risk	Current Effectiveness	Owner	Review Date	Residual Risk
Operational	09. STRATEGIC Failure to meet key performance indicators which could result in poor clinical outcomes, financial penalties and reputational damage	Significant	Moderate	Tim Jones		29/11/2013	Moderate

Controls		Assurances		Gaps	
Description	Gaps	Effectiveness	Internal	External	Gaps
Informatics to develop an automated report on the dashboard so that researchers can clearly see when the 70 day target is for their studies.	Dashboard not yet complete.	R&D Operations team are regularly updating research staff directly		NHfR target submissions	
Monitoring of CQUINS	Gaps	H			
Study feasibility meetings with key leads to ensure any problems with studies are identified early so that corrective action can be taken.	Issues with studies highlighted and addressed in meeting. Within the R&D financial planning and the December CEAG paper the increase in activity posts within R&D has been demonstrated to justify the need for the Annex U posts.	The feasibility meetings have been running since September. CEAG Papers. R&D Financial planning.			
Controls	Gaps	Effectiveness	Internal	External	Gaps
Description	Gaps	Effectiveness	Internal	External	Gaps
Monitoring of CQUINS	Risks to achievement discussed and challenged at monthly Performance and Data Quality meetings.	H	Monthly updates to CQMG, KPI reports to BoD, CEAG and COOG re COIN implementation progress and risks to achievement. Strategy and Performance monthly monitoring.	Monitoring with Clinical Commissioning Group.	Realtime reports and dashboards being developed.
Monitoring of CQUINS	Gaps	H			
Study feasibility meetings with key leads to ensure any problems with studies are identified early so that corrective action can be taken.	Issues with studies highlighted and addressed in meeting. Within the R&D financial planning and the December CEAG paper the increase in activity posts within R&D has been demonstrated to justify the need for the Annex U posts.	H	The feasibility meetings have been running since September. CEAG Papers. R&D Financial planning.		